AngelaDeMicheleMDMSCE

PubMed

• PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...
  Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara Abdou, Elizabeth C Riley, ...> ;Journal of Clinical Oncology. 2024 Mar 21
• Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination.
  Lawrence-Paul, M., Pan, T., Pant, D., Shih, N., Chen, Y., Belka, G., Feldman, M., DeMichele, A., Chodosh, L.> ;Genome Medicine. 2024 Feb 6
• Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
  Smith, K., Zhao, F., Mayer, I., Tevaarwerk, A., Garcia, S., Arteaga, C., Symmans, W., Park, B., Burnette, B., Makower, D., Block, M., Morley, K., Jani, C., Mescher, C....> ;Cancer. 2024 Jan 18
• Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
  Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien, Anne M Wallace, Andres Forero-Torres, Lajos Pusztai, Erin D Ellis, Kathy S Albain...> ;JAMA Network Open. 2023 Dec 1
• 2 citations
  Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
  Angela DeMichele, Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Dongrui Ray Lu, Kathleen M Aguilar, Yunfei Wang, Benjamin Li, Sebastian Schneeweiss, Jeremy A Ras...> ;Targeted Oncology. 2023 Jul 1
• 1 citations
  Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.
  Michael G Fradley, Nam H K Nguyen, David Madnick, Yiqing Chen, Angela DeMichele, Igor Makhlin, Susan Dent, Benedicte Lefebvre, Joseph Carver, Jenica N Upshaw, David De...> ;Journal of the American Heart Association. 2023 Jun 20
• 1 citations
  Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
  Rhea Chitalia, Marios Miliotis, Nariman Jahani, Spyros Tastsoglou, Elizabeth S McDonald, Vivian Belenky, Eric A Cohen, David Newitt, Laura J Van't Veer, Laura Esserman...> ;Communications Medicine. 2023 Mar 30
• 2 citations
  Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database ana...
  Hope S Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Massimo Cristofanilli, Mylin A Torres, Giuseppe Curigliano, Richard S F...> ;Future Oncology. 2023 Mar 1
• 1 citations
  Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast c...
  Mark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, A Jo Chien, Judy C Boughey, Hyo S Han, Anne Wallace, Heather Beckwith, Minetta C Liu, Christina Yau, E Paul Wile...> ;Breast Cancer Research and Treatment. 2023 Apr 1
• 4 citations
  PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.
  Saisai Chen, Matt R Paul, Christopher J Sterner, George K Belka, Dezhen Wang, Peining Xu, Amulya Sreekumar, Tien-Chi Pan, Dhruv K Pant, Igor Makhlin, Angela DeMichele,...> ;Breast Cancer Research. 2023 Jan 3
• 6 citations
  Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
  Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A Parker, A Jo Chien, Anne M Wallace, Rashmi Murthy, Kathy S Albain, Er...> ;NPJ Breast Cancer. 2022 Dec 1
• 2 citations
  Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.
  Igor Makhlin, Nicholas P McAndrew, E Paul Wileyto, Amy S Clark, Robin Holmes, Lisa N Bottalico, Clementina Mesaros, Ian A Blair, Grace R Jeschke, Kevin R Fox, Susan M ...> ;NPJ Breast Cancer. 2022 Nov 11
• 16 citations
  Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.
  Siri H Strand, Belén Rivero-Gutiérrez, Kathleen E Houlahan, Jose A Seoane, Lorraine M King, Tyler Risom, Lunden A Simpson, Sujay Vennam, Aziz Khan, Luis Cisneros, Timo...> ;Cancer Cell. 2022 Dec 12
• 27 citations
  Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
  Hope S Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Massimo Cristofanilli, Mylin A Torres, Giuseppe Curigliano, Richard S F...> ;NPJ Breast Cancer. 2022 Oct 11
• 2 citations
  Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A.
  Amy S Clark, Erin F Cobain, Zoneddy Dayao, Mark R Somerfield, Angela DeMichele, N Lynn Henry> ;JCO Oncology Practice. 2022 Dec 1
• 1 citations
  The effects of exercise and diet on sex steroids in breast cancer survivors.
  Justin C Brown, Kathleen Sturgeon, David B Sarwer, Andrea B Troxel, Angela M DeMichele, Crystal S Denlinger, Kathryn H Schmitz> ;Endocrine-Related Cancer. 2022 Aug 1
• 28 citations
  Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
  N Lynn Henry, Mark R Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M McShane, Beverly Moy, Ben Ho Park, Kelly M Shanahan, Priyanka Sharma, Rebecca Sha...> ;Journal of Clinical Oncology. 2022 Sep 20
• 3 citations
  Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.
  Igor Makhlin, Angela DeMichele> ;Cell Reports. Medicine. 2022 Jun 21
• 73 citations
  Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
  Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark J Magbanua, Rosalyn Sayaman, Nicholas O'Gr...> ;Cancer Cell. 2022 Jun 13
• 1 citations
  Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?
  David W Cescon, Kevin Kalinsky, Angela M DeMichele> ;Journal of Clinical Oncology. 2022 Aug 1
• 2 citations
  Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACR...
  Snekha Thakran, Eric Cohen, Nariman Jahani, Susan P Weinstein, Lauren Pantalone, Nola Hylton, David Newitt, Angela DeMichele, Christos Davatzikos, Despina Kontos> ;Translational Oncology. 2022 Jun 1
• 53 citations
  Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
  Massimo Cristofanilli, Hope S Rugo, Seock-Ah Im, Dennis J Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroj...> ;Clinical Cancer Research. 2022 Aug 15
• 9 citations
  Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer tri...
  M Marczyk, A Mrukwa, C Yau, D Wolf, Y-Y Chen, R Balassanian, R Nanda, B A Parker, G Krings, H Sattar, J C Zeck, K S Albain, J C Boughey, M C Liu, A D Elias, A S Clark,...> ;Annals of Oncology. 2022 Aug 1
• 6 citations
  Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy.
  Yehoda M Martei, Dipho I Setlhako, Gezahen Ayane, Tlotlo Ralefala, Sebathu Chiyapo, Robert Gross, Lawrence N Shulman, Surbhi Grover, Angela DeMichele, Narasimhamurthy, M.> ;JCO Global Oncology. 2022 May 1
• 19 citations
  Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
  Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Alice C Fan, Angela DeMichele, Naomi B Haas, Manish R Patel, James J Harding, M...> ;Clinical Cancer Research. 2022 Apr 14
• Join now to see all

Journal Articles

• Distinct Microbial Signatures Associated with Different Breast Cancer Types  
  Angela M. DeMichele, Michael D. Feldman, Frontiers in Neurology
• Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer  
  Austin D Williams, Amy S Clark, Paul J Zhang, Julia Tchou, Bruce L Levine, Jennifer M Matro, Laurence J Cooper, Alycia So, Lynn M Schuchter, Carl H June, Angela M DeMi..., Clinical Cancer Research
• A randomized trial of electro-accupuncture for arthralgia related to aromatase inhibitor use  
  Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A, European Journal of Cancer, 1/1/2014
• Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability  
  LeBlanc M, Stineman M, DeMichele A, Stricker C, Mao JJ, Archives of Physical Medicine and Rehabilitation, 1/1/2014
• Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY Trial (CALGB 150007)  
  Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A, I-SPY1 Investigators, Cancer Medicine, 1/1/2014
• Expectancy in real and sham acupuncture: does believing make it so?  
  Bauml J, Xie S, Farrar J, Bruner D, Stricker C, Bowman M, DeMichele A, Mao J, Journal of Alternative and Complementary Medicine, 1/1/2014
• Metrics to evaluate treatment summaries and survivorship care plans: A scorecard  
  Palmer SC, Jacobs LA, DeMichele A, Risendal B, Jones AF, Stricker CT, Supportive Care in Cancer, 1/1/2014
• Physical Activity and Telomere length in early stage breast cancer Survivors  
  Garland SN, Johnson B, Palmer C, Speck RM, Donelson M, Xie SX, DeMichelle A, Breast Cancer, 1/1/2014
• Acclerated approval for pertuzumab in the neoadjvuant setting: Winds of change?  
  Esserman L, DeMichele A, Clinical Cancer Research, 1/1/2014
• Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors  
  Desai K, Mao JJ, Su I, DeMichele A, Li Q, Xie SX, Gehrman PR, Supportive Care in Cancer, 1/1/2013
• mir-30d regulated multiple genes in the autophagy pathway and impairs autophagy process in human cancer  
  Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L, Biochem Biophys Res Commun, 1/1/2013
• Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials  
  Demichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Jo Chien A, Haluska P,..., Clinical Cancer Research, 1/1/2013
• Association of progesterone receptor gene (PGR) variants and breast cancer risk in African American women  
  Gabriel CA, Mitra N, DeMichele A, Rebbeck T, Breast Cancer Research and Treatment, 1/1/2013
• Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors  
  Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ, BMC Cancer, 1/1/2013
• Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in non-metastatic breast cancer  
  Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A, Journal of Oncology Practice, 1/1/2013
• Phase 1, Dose-escalation Trial of the Oral Cyclin-dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-day Schedule in Patients with Advanced Cancer  
  Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, Shaik MN, Wilner KD,O'Dwyer PJ, Schwartz GK, Clinical Cancer Research, 1/1/2012
• Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients  
  Speck RM, DeMichele A, Farrar JA, Hennessy S, Mao JJ, Stineman MG and Barg FK, Supportive Care in Cancer, 1/1/2012
• The role of lapatinib in the preoperative therapy of breast cancer  
  Hirsh RL, DeMichele A, Curr Oncology Rep, 1/1/2012
• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 15007/150012: ACRI...  
  Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, Van't Veer LJ, Hudis C, Chin K, Wol..., Breast Cancer Research and Treatment, 1/1/2012
• Vitamin D Deficiency in Post-menopausal Breast Cancer Survivors  
  Freidman C, DeMichele A, Su HI, Feng R, Kapoor S, Desai K, Mao JJ, Journal of Women's Health, 1/1/2012
• Is screening effective in detecting untreated psychiatric disorders among newly diagnosed breast cancer patients?  
  Palmer SC, Taggi A, DeMichele A, Coyne JC, Cancer, 1/1/2012
• CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients  
  Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinback LI, Pletcher CH, Tweed CK, DeMichele A, Fox KR, Domchek SM, Riley JL, Vonde..., Science Translational Medicine, 1/1/2012
• A genome-wide association study of breast cancer in women of African ancestry  
  Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR, Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, Press M..., Human Genetics, 1/1/2012
• Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies  
  Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK, Supportive Care in Cancer, 1/1/2012
• Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)  
  Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton ME, Hudis C, Gray J, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, O..., Journal of Clinical Oncology, 1/1/2012
• Join now to see all

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: Drug development: Neoadjuvant opportunities in breast cancer. 
  Page 73 - 79Rastogi P, Geyer CE, Mamounas EP, Demichele A2013
• American Society of Clinical Oncology Education Book 
  Chapter: Adherence to Oral Cancer Therapies: Challenges and Opportunities. 
  Partridge A, Kato P, DeMichele AAmerican Society of Clinical Oncology2010
• Textbook of Clinical Trials 
  Chapter: Systematic Review and Meta-Analysis. 
  Brunelli SM, DeMichele A, Guevara J, Berlin J2010
• Diseases of the Breast 
  Chapter: Loco-Regional Recurrence After Breast Conservation Therapy or Mastectomy. 
  Solin LJ, Harris E, Orel S, DeMichele A, Tchou JEditors: Lippman M, Morrow M, Osborne K.Lippincott Williams and Wilkens2009
• Handbook of Cancer Survivorship 
  Chapter: Comprehensive long term follow-up: cancer survivorship centers. 
  Jacobs LJ., Alavi J., DeMichele A., Palmer S., Stricker C., Vaughn D.2007
• Clinical Oncology 
  Chapter: Cancer-Related Emergencies. 
  DeMichele AM, Glick JHEditors: Hall, L.American Cancer Society2001
• Geriatric Secrets 
  Chapter: Care of the Elderly Cancer Patient. 
  DeMichele AM, Greenberg RH, Vaughn DJEditors: Forciea M, Schwab E, Lavizzo-Mourey R.Hanley and Belfus, Philadelphia, PAEdition 2nd,1999
• Geriatric Secrets 
  Chapter: Cancer Screening in the Elderly. 
  DeMichele AM, Greenberg RH, Vaughn DJEditors: Forciea M, Schwab E, Lavizzo-Mourey R.Hanley and Belfus, Philadelphia, PAEdition 2nd,1999
• Diseases of the Breast 
  Chapter: Inherited Genetic Factors. 
  DeMichele AM, Weber BLEditors: Harris J, Morrow M, Lippman S.Harris J, Morrow M, Lippman, Philadelphia, PAEdition 2nd,1999
• Join now to see all

Abstracts/Posters

• A Phase II Trial of the CDK 4/6 Inhibitor PD0332991 in Advanced Breast Cancer.
  DeMichele A, Clark A, Tan KS, Heitjan D, Randolph S, Christensen J, Gallagher M, Lal P, Feldman M, Zhang P, Domchek S, Gogineni K, Keefe S, Rosen M, Fox K, O'Dwyer P, American Society of Clinical Oncology, 1/1/2013

Lectures

• "San Antonio Update 2013" 
  Morristown, NJ - 1/1/2014
• "Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL" 
  Philadelphia, PA - 1/1/2014
• "Palbociclib in Breast Cancer" 
  Washington, DC - 1/1/2014
• "The I-SPY2 Trial: A New Paradigm to Speed Drug Development and Approval" 
  Washington, DC - 1/1/2014
• "Drug Development in the Neoadjuvant Setting: Challenges and Opportunities" 
  Toronto, Canada - 1/1/2014
• "The I-SPY2 Trial: Using Biomarkers to Assess New Therapies in Early Breast Cancer" 
  Washington, DC - 1/1/2014
• "The I-SPY2 TRIAL: Early Results Evaluating New Agents for Breast Cancer" 
  Toronto, Canada - 1/1/2014
• "CDK 4/6 Inhibition in Breast Cancer" 
  Madrid, Spain - 1/1/2014
• "Neoadjvuant Therapy as a Mechanism for Drug Approval" 
  San Francisco, CA - 1/1/2014
• "SABCS 2012:Update on new targets, molecular tools and insights into triple negative disease" 
  Morristown, NJ - 1/1/2013
• "Highlights of the San Antonio Breast Cancer Symposium: Targeted Therapy" 
  Fox Chase Cancer Center, Philadelphia, PA - 1/1/2013
• Pushing the Limits of Upfront Care and Drug Development: Neoadjuvant Trial Opportunities in Breast Cancer. 
  Chicago, IL - 1/1/2013
• "Design of the I-SPY2 Trial" 
  Brussels, Belgium - 1/1/2013
• "I-SPY2: An adaptive trial of targeted therapy in the neoadjuvant treatment of breast cancer" 
  Bethesda, MD - 1/1/2012
• "Challenges of Drug Development in the Neoadjuvant Setting" 
  Montreal - 1/1/2012
• "Neoadjuvant Clinical Trial Opportunities for ER+ Breast Cancer" 
  Bethesda, MD - 1/1/2012
• "Drug Development in the Neoadjuvant Setting: Lessons from the I-SPY2 Trial" 
  Hotel DelCoronado, CA - 1/1/2012
• "Targeted therapy for advanced breast cancer: Past, present and the future" 
  Harrisburg, PA - 1/1/2012
• "Drug and Biomarker Development in Breast Cancer" 
  San Francisco, CA - 1/1/2012
• "Clinical Trial Designs for New Therapies: What Agents Should Go into Trials?" 
  San Antonio, TX - 1/1/2012
• "Neoadjuvant Therapeutic and Biomarker Development: The ISPY Research Program" 
  Washington, DC - 1/1/2011
• "Cyclin Dependent Kinases as a Target for Breast Cancer Therapy." 
  Sun Valley, ID - 1/1/2011
• "Early-Stage Breast Cancer: Treatment and Living Well Beyond" 
  Philadelphia, PA - 1/1/2011
• "Breast Cancer Update: Abstracts from the 2010 ASCO National Meeting" 
  Carol G. Simon Cancer Center, Morristown Memorial Hospital, Morristown, NJ - 1/1/2010
• "The I-SPY2 Trial: A new paradigm for therapeutic biomarker development" 
  Princeton, NJ - 1/1/2010
• Join now to see all